Oramed Pharmaceuticals, Inc. (ORMP) is higher by 1.54% Monday In Premarket Trading

Oramed Pharmaceuticals, Inc. (ORMP) is higher by Monday morning, with the stock rising 1.54% in pre-market trading to 3.3. ORMP's short-term technical score of 56 indicates that the stock has traded more bullishly over the last month than 56% of stocks on the market. In the Biotechnology industry, which ranks 109 out of 146 industries, the stock ranks higher than 69% of stocks. Oramed Pharmaceuticals, Inc. has fallen 17.93% over the past month, closing at $4.02 on May 29. During this period of time, the stock fell as low as $3.25 and as high as $4.36. ORMP has an average analyst recommendation of Sell. The company has an average price target of $3.65.

ORMP has an Overall Score of 48. Find out what this means to you and get the rest of the rankings on ORMP!

See Full ORMP Report

Oramed Pharmaceuticals, Inc. has a Long-Term Technical rank of 66. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 34% of the market scoring higher. In the Biotechnology industry which is number 91 by this metric, ORMP ranks better than 91% of stocks.

Important Dates for Investors in ORMP:

-Oramed Pharmaceuticals, Inc. is set to release earnings on 8/9/2023. Over the last 12 months, the company has reported EPS of $0.52. -We do not have a set dividend date for Oramed Pharmaceuticals, Inc. at this time. Click Here To Get The Full Report on Oramed Pharmaceuticals, Inc. (ORMP)